#
# List of treatments for testing.  Each line is the following format:
#
# Gene\tVariant\tTumorType\tTreatments\tLevel
#
KIT	N505I	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib;
KIT	N505L	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib;
KIT	M541L	
KIT	M541C	
KIT	Y553N	
KIT	Y553C	
KIT	R643W	
KIT	D737N	
KIT	C809G	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Gastrointestinal Stromal Tumor): Sorafenib; 4 (Gastrointestinal Stromal Tumor): Nilotinib; 4 (Gastrointestinal Stromal Tumor): Pazopanib; R2 (Gastrointestinal Stromal Tumor): Imatinib; R2 (Gastrointestinal Stromal Tumor): Sunitinib;
KIT	K642E	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Melanoma): Imatinib;
KIT	K642G	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib;
KIT	V654A	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Melanoma): Imatinib; R2 (Gastrointestinal Stromal Tumor): Imatinib;
KIT	V654G	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib;
KIT	T670I	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; R2 (Gastrointestinal Stromal Tumor): Imatinib;
KIT	T670C	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib;
KIT	D816A	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Mastocytosis): Avapritinib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Gastrointestinal Stromal Tumor): Sorafenib; 4 (Gastrointestinal Stromal Tumor): Nilotinib; 4 (Gastrointestinal Stromal Tumor): Pazopanib; R2 (Gastrointestinal Stromal Tumor): Imatinib; R2 (Gastrointestinal Stromal Tumor): Sunitinib;
KIT	Y823D	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Gastrointestinal Stromal Tumor): Sorafenib; 4 (Gastrointestinal Stromal Tumor): Nilotinib; 4 (Gastrointestinal Stromal Tumor): Pazopanib; R2 (Gastrointestinal Stromal Tumor): Imatinib; R2 (Gastrointestinal Stromal Tumor): Sunitinib;
KIT	Y823G	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib;
KIT	A829P	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Gastrointestinal Stromal Tumor): Sorafenib; 4 (Gastrointestinal Stromal Tumor): Nilotinib; 4 (Gastrointestinal Stromal Tumor): Pazopanib; R2 (Gastrointestinal Stromal Tumor): Imatinib; R2 (Gastrointestinal Stromal Tumor): Sunitinib;
KIT	D820G	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Gastrointestinal Stromal Tumor): Sorafenib; 4 (Gastrointestinal Stromal Tumor): Nilotinib; 4 (Gastrointestinal Stromal Tumor): Pazopanib; R2 (Gastrointestinal Stromal Tumor): Imatinib; R2 (Gastrointestinal Stromal Tumor): Sunitinib;
KIT	N822E	1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Sunitinib; 1 (Gastrointestinal Stromal Tumor): Regorafenib; 1 (Gastrointestinal Stromal Tumor): Ripretinib; 2 (Gastrointestinal Stromal Tumor): Sorafenib; 4 (Gastrointestinal Stromal Tumor): Nilotinib; 4 (Gastrointestinal Stromal Tumor): Pazopanib; R2 (Gastrointestinal Stromal Tumor): Imatinib; R2 (Gastrointestinal Stromal Tumor): Sunitinib;
MTOR	L2427Q	3A (Renal Cell Carcinoma): Temsirolimus;
PDGFRA	D842I	1 (Gastrointestinal Stromal Tumor): Avapritinib; 2 (Gastrointestinal Stromal Tumor): Imatinib; 2 (Gastrointestinal Stromal Tumor): Sunitinib; 2 (Gastrointestinal Stromal Tumor): Regorafenib; 2 (Gastrointestinal Stromal Tumor): Ripretinib;
PDGFRA	D842V	R1 (Gastrointestinal Stromal Tumor): Imatinib; 1 (Gastrointestinal Stromal Tumor): Avapritinib; 2 (Gastrointestinal Stromal Tumor): Dasatinib; 2 (Gastrointestinal Stromal Tumor): Imatinib; 2 (Gastrointestinal Stromal Tumor): Sunitinib; 2 (Gastrointestinal Stromal Tumor): Regorafenib; 2 (Gastrointestinal Stromal Tumor): Ripretinib;
EGFR	A763_Y764insFQEA	1 (Non-Small Cell Lung Cancer): Amivantamab; 1 (Non-Small Cell Lung Cancer): Mobocertinib; 1 (Non-Small Cell Lung Cancer): Amivantamab+Chemotherapy; 2 (Non-Small Cell Lung Cancer): Erlotinib; 3A (Non-Small Cell Lung Cancer): Poziotinib; 3A (Non-Small Cell Lung Cancer): CLN-081; 4 (Non-Small Cell Lung Cancer): Afatinib;

# this one overlaps with A763_Y764insFQEA, but the rule only applies to exact match, so R1 will be used	
EGFR	Y764_D770dup	R1 (Non-Small Cell Lung Cancer): Erlotinib; R1 (Non-Small Cell Lung Cancer): Gefitinib; R1 (Non-Small Cell Lung Cancer): Afatinib; 1 (Non-Small Cell Lung Cancer): Amivantamab; 1 (Non-Small Cell Lung Cancer): Mobocertinib; 1 (Non-Small Cell Lung Cancer): Amivantamab+Chemotherapy; 2 (Non-Small Cell Lung Cancer): Erlotinib; 3A (Non-Small Cell Lung Cancer): Poziotinib; 3A (Non-Small Cell Lung Cancer): CLN-081; 4 (Non-Small Cell Lung Cancer): Afatinib;

# this one does not overlap with A763_Y764insFQEA, so R1 for sure
EGFR	N771delinsSTH	R1 (Non-Small Cell Lung Cancer): Erlotinib; R1 (Non-Small Cell Lung Cancer): Gefitinib; R1 (Non-Small Cell Lung Cancer): Afatinib; 1 (Non-Small Cell Lung Cancer): Amivantamab; 1 (Non-Small Cell Lung Cancer): Mobocertinib; 1 (Non-Small Cell Lung Cancer): Amivantamab+Chemotherapy; 3A (Non-Small Cell Lung Cancer): Poziotinib; 3A (Non-Small Cell Lung Cancer): CLN-081;

# BRACA Oncogenic Mutations has evdience includes multiple cancer types
BRCA1	Oncogenic Mutations	1 (Ovarian Cancer): Olaparib; 1 (Ovary/Fallopian Tube): Olaparib; 1 (Peritoneal Serous Carcinoma): Olaparib; 1 (Prostate Cancer, NOS): Olaparib; 1 (Prostate Cancer): Olaparib; 1 (Ovarian Cancer): Olaparib+Bevacizumab; 1 (Ovary/Fallopian Tube): Olaparib+Bevacizumab; 1 (Peritoneal Serous Carcinoma): Olaparib+Bevacizumab; 1 (Prostate Cancer, NOS): Rucaparib; 1 (Prostate Cancer): Rucaparib; 1 (Prostate Cancer, NOS): Olaparib+Abiraterone+Prednisone; 1 (Prostate Cancer): Olaparib+Abiraterone+Prednisone; 1 (Ovarian Cancer): Rucaparib; 1 (Ovary/Fallopian Tube): Rucaparib; 1 (Peritoneal Serous Carcinoma): Rucaparib; 1 (Ovarian Cancer): Niraparib; 1 (Ovary/Fallopian Tube): Niraparib; 1 (Peritoneal Serous Carcinoma): Niraparib; 1 (Prostate Cancer, NOS): Olaparib+Abiraterone+Prednisolone; 1 (Prostate Cancer): Olaparib+Abiraterone+Prednisolone; 1 (Prostate Cancer, NOS): Talazoparib+Enzalutamide; 1 (Prostate Cancer): Talazoparib+Enzalutamide; 1 (Prostate Cancer, NOS): Niraparib+Abiraterone Acetate+Prednisone; 1 (Prostate Cancer): Niraparib+Abiraterone Acetate+Prednisone; 2 (Pancreatic Adenocarcinoma): Rucaparib; 2 (Acinar Cell Carcinoma of the Pancreas): Rucaparib; 3A (Pancreatic Adenocarcinoma): Olaparib; 3A (Acinar Cell Carcinoma of the Pancreas): Olaparib; 3A (Breast Cancer): Talazoparib; 3A (Breast Cancer): Olaparib;

# Likely neutral/Inconclusive variant should not have any treatments associated
PDGFRA	K830R	
BRAF	V600M	

# ESR1 oncogenic ligand-binding domain mutations
ESR1	S463P	1 (Breast Cancer): Elacestrant; 3A (Breast Cancer): Fulvestrant;
ESR1	S432L	
ESR1	S432del		
ESR1	V422del	2 (Breast Cancer): Elacestrant; 3A (Breast Cancer): Fulvestrant;